Amedica's Taurus™ Pedicle Screw generated ~US $1.3MM in 2017 revenue and was employed in >250 procedures since its 1Q17 launch. Taurus and Valeo II silicon nitride implants contributed to a 40% increase in AMDA's surgeon customers during 2017.
Also during 2017, the company grew its sales channel in the U.K. and identified potential distribution partners in Australia.
For 2018, AMDA expects to launch several new products and publish data from a review of its large-scale clinical outcomes with silicon nitride spinal interbody devices, as well as results from the Level 1 SNAP lumbar spine clinical trial.
Finally, AMDA has received FDA feedback on its 510(k) submission for the C+CSC with Lumen implant and is submitting a response.
Amedica's Taurus™ Pedicle Screw generated ~US $1.3MM in 2017 revenue and was employed in >250 procedures since its 1Q17 launch. Taurus and Valeo II silicon nitride implants contributed to a 40% increase in AMDA's surgeon customers during 2017. Also during 2017, the company grew its sales channel in the U.K. and identified...
Amedica's Taurus™ Pedicle Screw generated ~US $1.3MM in 2017 revenue and was employed in >250 procedures since its 1Q17 launch. Taurus and Valeo II silicon nitride implants contributed to a 40% increase in AMDA's surgeon customers during 2017.
Also during 2017, the company grew its sales channel in the U.K. and identified potential distribution partners in Australia.
For 2018, AMDA expects to launch several new products and publish data from a review of its large-scale clinical outcomes with silicon nitride spinal interbody devices, as well as results from the Level 1 SNAP lumbar spine clinical trial.
Finally, AMDA has received FDA feedback on its 510(k) submission for the C+CSC with Lumen implant and is submitting a response.
Copy to clipboard 
